FDA chief to depart after Trump signed off on ousting him

FDA Chief to Depart After Trump Signed Off on Ousting Him

FDA chief to depart after Trump – President Donald Trump has given the green light to remove Food and Drug Administration (FDA) Commissioner Marty Makary from his position, according to three individuals close to the situation. The decision comes as Makary prepares to leave the Trump administration, marking another shift in leadership within the Health and Human Services Department. His departure follows weeks of mounting pressure from within the White House and from external stakeholders, including pharmaceutical firms and anti-abortion advocacy groups, who had grown frustrated with his policies and management style.

Internal and External Tensions Fuel Ouster

Makary’s leadership at the FDA has been strained by internal disagreements and external criticism. Within the administration, there was persistent pushback over his refusal to approve the sale of flavored e-cigarettes, a decision that became a flashpoint during direct confrontations with Trump. Outside the government, his stance on vaping products drew scrutiny from industry leaders and conservative allies, who viewed his approach as an obstacle to regulatory flexibility. Additionally, the agency has experienced frequent leadership changes, with senior roles vacating regularly due to conflicts and shifting priorities.

Trump’s approval of Makary’s removal was confirmed in a post on Truth Social, where he highlighted the decision. The president’s deputy commissioner, Kyle Diamantas, who leads the agency’s food program, is set to serve as the acting FDA chief. This move signals a broader effort to consolidate control over the FDA’s operations, aligning them more closely with the administration’s current agenda. Makary’s resignation, however, has left Trump with the task of selecting a permanent replacement, a process requiring Senate approval and adding to the list of critical health department vacancies.

Senate Confirmation and Leadership Gaps

As of now, the permanent successor to the FDA commissioner position is yet to be named, according to two sources with knowledge of the decision. This marks the latest in a series of leadership gaps within the Health and Human Services Department, which already lacks a confirmed head for the Centers for Disease Control and Prevention (CDC) and a permanent surgeon general. The surgeon general, typically the nation’s top medical authority, has also been absent from the role for an extended period, raising concerns about the consistency of health policy direction.

Health and Human Services Secretary Robert F. Kennedy Jr. recently expressed support for Makary’s work in a post on X, emphasizing the urgency of finding a new commissioner. “The search for a new Commissioner is already underway, and we will move forward with urgency,” he wrote. Despite this endorsement, the decision to replace Makary reflects a strategic realignment, with Trump aiming to streamline decision-making and strengthen ties with key constituencies such as the anti-abortion movement and the pharmaceutical industry.

The Vape Controversy and Policy Reversals

Makary’s most contentious issue centered on the regulation of flavored e-cigarettes. While he opposed approving youth-friendly flavors, arguing they contributed to rising vaping rates among adolescents, the administration pushed for a reversal. This disagreement escalated to a confrontation, with Trump directly challenging Makary’s position during a recent meeting. The FDA eventually relented, reversing its stance on flavored e-cigarettes and approving their sale, a decision that appears to have sealed Makary’s fate.

As the head of the FDA, Makary faced mounting pressure from multiple fronts. Within the agency, internal factions clashed over policy direction, particularly regarding tobacco and drug approvals. Outside the government, critics accused him of bureaucratic rigidity, citing delays in key decisions that frustrated industry partners and allies. His tenure has been marked by a series of policy reversals, including the recent shift on vaping regulations, which underscores the challenges he encountered in balancing regulatory oversight with political priorities.

Political Strategy and Midterm Considerations

Some Trump advisors initially hesitated to remove Makary, fearing it could alienate portions of the administration’s base. The “Make America Healthy Again” coalition, which has been a vocal supporter of health reforms, might perceive the move as a symbolic setback. However, others within the White House and HHS viewed the change as necessary to address perceived inefficiencies and align the FDA with the administration’s vision for health policy. The decision also aims to reduce the number of high-level vacancies, ensuring smoother operations ahead of the midterm elections.

The timing of Makary’s departure adds another layer of complexity. His planned testimony before the Senate Appropriations Committee on the FDA’s proposed budget was set to occur just one day after his resignation was announced. This has sparked questions about the administration’s internal dynamics, as some officials believed the president still had confidence in Makary’s leadership. The abrupt reversal of his position on flavored e-cigarettes, coupled with growing dissatisfaction over the FDA’s operational chaos, likely accelerated the process.

Legacy of Controversy and Leadership Challenges

Makary, a surgeon and author, was appointed in March 2025 with a mandate to expedite FDA decisions on drugs, devices, and vaccines. Yet, his time in office has been overshadowed by controversies, particularly in the pharmaceutical sector. Companies criticized his management of the drug approval process, arguing it slowed innovation and delayed critical treatments. Meanwhile, internal debates over tobacco regulation and other policy areas further complicated his role.

Despite his efforts to stabilize the FDA’s operations, the agency has remained a target for restructuring. White House and HHS officials are now considering a broader overhaul of the FDA’s senior staff, aiming to centralize authority and improve coordination. This comes as the administration seeks to position itself for the upcoming election cycle, ensuring its health policies resonate with both political allies and the general public. Makary’s departure underscores the challenges of maintaining institutional coherence in a leadership-driven political environment.

In a recent meeting with White House officials, Susan B. Anthony Pro-Life America’s President Marjorie Dannenfelser played a pivotal role in advocating for changes to FDA regulations affecting reproductive health. Her involvement highlights the influence of external groups in shaping the agency’s priorities, a trend that has intensified under Trump’s administration. The FDA’s reversal on flavored e-cigarettes is just one example of how internal and external pressures have converged to reshape its policies.

While Makary’s resignation has been confirmed, the broader implications of the move are still unfolding. His exit may lead to a more unified FDA under Diamantas, but it also raises questions about the sustainability of the administration’s approach to regulatory leadership. With the Senate now tasked with confirming a new commissioner, the political stakes are high, and the process could impact the timeline for key health initiatives. For now, the focus remains on the transition, as the FDA prepares to implement new policies under its new leadership.

“He doesn’t want to approve youth-appealing flavors, but has been forced to by the powers that be,” said a source close to Makary’s departure. This quote encapsulates the internal struggle at the FDA, where Makary’s personal convictions often clashed with the administration’s broader objectives. His resignation, therefore, represents not just a personnel change but a shift in the ideological direction of the agency, reflecting the evolving priorities of the Trump administration.